PURPOSE: Rectal prolapse is a commonly occurring and usually self-limited process in children. Surgical management is indicated for failures of conservative management. However, the optimal approach is unknown. The purpose of this study is to determine the efficacy of sclerotherapy for the management of rectal prolapse.
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TYPE OF STUDY: Treatment Study
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INTRODUCTION:
Rectal prolapse is a relatively common condition in children that typically occurs before the year of four, around the time toilet training begins [1] [2] [3] [4] . It is most frequently idiopathic and self-limited and resolves with improved toileting habits and stool softeners within one year in the majority of patients [1] [2] [3] [4] [5] [6] . If prolapse persists despite optimal management, various strategies exist for treatment. These include injection sclerotherapy [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , encircling of the anus, also known as the Thiersch operation [10, 18] , abdominal operations [3, 13, 19, 20] , and perineal operations [10, 21] . Given the varied approaches, no one technique currently predominates thereby creating a wide heterogeneity in practice patterns.
Sclerotherapy has several potential advantages including its minimally invasive nature and low complication profile [4] . We seek to determine the success of injection sclerotherapy in patients with rectal prolapse who failed conservative management in a large, tertiary academic center. We also aim to characterize factors associated with failure of sclerotherapy to determine if there are patients who may benefit from initial operative management.
MATERIALS AND METHODS:
This is a single institution retrospective review of patients less than 18 years old who underwent injection sclerotherapy for rectal prolapse between 1998 and 2015. Patients with imperforate anus or cloaca abnormalities, Hirschprung's disease, or prior pull-through procedures were excluded. Additionally, two patients who underwent primary rectopexy were excluded. Appropriate institutional review board approval was obtained prior to initiating the study.
Patients with rectal prolapse were treated via a standard pathway. This standard pathway included initial medical management with fiber supplementation in all patients. If patients had constipation, they were treated with laxatives. Behavior modification was used in all patients which included minimizing time on the toilet and avoiding. If medical management failed to resolve the prolapse in 1-3 months, patients were considered for injection sclerotherapy. The A C C E P T E D M A N U S C R I P T 
RESULTS:
Fifty-seven patients undergoing injection sclerotherapy were included for analysis.
Patient demographics, operative characteristics, and post-operative results are given in Table 1 .
Patients were followed for a median of 52 months (IQR: 7.6-91.0 months).
Phenol in peanut oil was the predominant sclerosant used (n=51/57; 91%). Three underwent repeated sclerotherapy. This was successful in five patients (n=5/9; 56%). Three patients were cured after 2 total rounds of sclerotherapy, one person was cured after 3 total rounds of sclerotherapy, and one person was cured after 4 total rounds of sclerotherapy, with treatment intervals from one months to several years. Thus, in total, sclerotherapy alone resulted in a durable cure of rectal prolapse in forty-four patients (n=44/57; 77%). Four patients who underwent repeated sclerotherapy (n=4/9; 44%) eventually required a rectopexy. One of these four patients required a sigmoidectomy and Hartmann pouch after failed rectopexy. Nine patients underwent rectopexy after one attempt at sclerotherapy. Two of these patients required another operation for rectal prolapse. This involved an excision of rectal procidentia with anastomosis via a perineal approach in one patient and a sigmoidectomy via abdominal approach in another patient. Thus, thirteen total patients (n=13/20; 65%) with recurrence following sclerotherapy underwent a rectopexy. Three of these patients (n=3/13; 23%) recurred and required another operative intervention.
In evaluating factors associated with recurrence, older age, higher weight, and sclerosant other than phenol in peanut oil were all significantly associated with recurrence (pvalue<0.05). All patients who used phenol in almond oil or dextrose solution experienced a recurrence. Two of the three patients with recurrence following phenol in almond oil sclerotherapy required rectopexy and the other patient was cured with repeated sclerotherapy.
Both patients with recurrence after dextrose injection sclerotherapy were cured with repeated sclerotherapy. Higher sclerosant volume was associated with recurrence (p-value=0.02).
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However, there was no association with sclerosant volume and recurrence after standardization patient weight (p-value=0.41).
In evaluating factors associated with eventual success of sclerotherapy or eventual requirement of operative management, similar factors to recurrence were associated with requirement for eventual operation, but the differences in groups are larger (Table 4) . Patients who required operative management were 7.9 years older on average and 28 kg heavier on average. There was a patient who was 18 years old and another who weighed 71 kg whose rectal prolapse was cured with sclerotherapy alone.
DISCUSSION:
In our single center retrospective review that spanned over 15 years, fifty-seven patients who underwent primary injection sclerotherapy for rectal prolapse were examined. This represents one of the largest series of injection sclerotherapy in the current literature. Our results demonstrate that the first sclerotherapy results in durable cure of prolapse in 68% of patients and repeat sclerotherapy will eventually result in a durable cure of prolapse in 77% of patients. This cure rate is similar to the current literature, in which injection sclerotherapy has been found to result in durable cure 70-95% of the time [4, 5, 8, 9, 11-13, 15, 16] . If a recurrence occurred, it most commonly occurred within the first four months, indicating that sclerotherapy also results in durable cure in the majority of our patients. Further, sclerotherapy was performed as an outpatient procedure in all cases and no complications occurred in patients who underwent sclerotherapy. While there have been reports of death following injection sclerotherapy due to phenol toxicity, the vast majority of reports on injection sclerotherapy have shown sclerotherapy is safe with minimal complications [4, 5, 8, 9, 11-13, 15, 16, 22] . One report noted an association of abscess formation with injection sclerotherapy with phenol in almond oil, and it may be that our process of dry-heat sterilization combined with batch culture prior to utilization in patients prevented this complication from occurring [15] .
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Injection sclerotherapy represents a safe, minimally invasive, and efficacious treatment of rectal prolapse.
Despite its efficacy, thirteen patients eventually required an abdominal operation to treat their rectal prolapse. In our evaluation of factors associated with recurrence and eventual need for operative management, several significant factors were noted. First, in comparing different sclerosants, our results demonstrate that all patients with phenol in almond oil and dextrose experienced recurrence. Both patients with dextrose sclerotherapy resolved with repeated sclerotherapy, but two of the three patients with phenol in almond oil required operative management. Phenol in almond oil has been found to be an effective sclerosant compared to cow's milk, 30% saline solution, 30% dextrose solution, and 70% ethyl alcohol solution [23] . In another study, phenol in almond oil was effective in all patients, but was associated with a 9% rate of abscess and mucosal sloughing in 27% [15] . In light of these studies and our study, phenol in peanut oil or concentrated dextrose should be the preferred sclerosant agent. In regards to volume, although there was not a statistically significant association, patients without recurrence had a median volume of 0.50 mL/kg of sclerosant compared with 0.38 mL/kg in patients who experienced a recurrence. Thus, a volume of 0.50 mL/kg of sclerosant divided over four quadrants appears a prudent volume to treat rectal prolapse.
Our study also highlights that older patients who weigh more are more likely to experience recurrence and eventually need an operation. This is congruent with prior studies that have investigated a relationship between age and recurrence following prolapse [13] . This has led other studies to recommend early definitive corrective surgery in older children (older than 5 years old) who do not respond to conservative measures or injection sclerotherapy [13] .
However, our results also highlight that patients as old as 18 years old or who weigh as much as 71 kg were successfully treated with sclerotherapy. Thus, a trial of sclerotherapy and at least one additional sclerotherapy appear reasonable given the favorable complication profile of this technique. Further, even amongst the thirteen patients who underwent surgical repair, three
required an additional operation (n=3/13; 23%), indicating that surgery itself is not a guarantee of successful resolution of prolapse.
These findings need to be viewed in light of limitations inherent in this method of investigation. One important potential limitation is that it is unknown how many of these patients would have had resolution of their prolapse without any treatment. While all patients were given a trial of conservative measures, we cannot know how many of the patients who underwent operative intervention would have had resolution of their symptoms without operative intervention. Another important limitation is potential losses to follow-up. While we had a robust median follow-up of 52 months and were able to utilize a statewide database to see if patients were treated at other facilities, it is still possible there were recurrences that were not captured as a result of the retrospective nature of this study. Thus, this study may overestimate the effectiveness of injection sclerotherapy. Another limitation is low power and number of events.
In particular, a multivariable analysis would be able to better define which factors are independently associated with recurrence. Unfortunately, with only twenty events of recurrence and only thirteen patients requiring operative management, we would only be able to include two factors into this analysis rendering this technique not particularly useful in our series.
CONCLUSIONS:
Injection sclerotherapy is an effective treatment strategy for children with rectal prolapse.
It should be the first-line treatment in patients who fail a trial of conservative management.
Repeat injection sclerotherapy should be the favored approach for recurrence. In older and heavier patients, consideration for earlier operative intervention should be considered. However, even these patients can benefit from a trial of injection sclerotherapy with a repeated treatment should a recurrence occur. Almond oil with phenol:
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Dextrose solution: MATTHEW LANDMAN: Based on this data and the practice, it's going to be less than a couple of months. I think if you don't have recurrence up front within that first two--month period, you can be a little bit more at ease about waiting longer. Within that first 1-2 months is a reasonable approach.
